Wednesday, June 20, 2018


VSAR Versartis, Inc. gains 33% Jun 20, 2018

Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. The company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase III clinical trials for the treatment of growth hormone deficiency. It develops drug candidates that it has licensed from Amunix Operating, Inc. The company was founded in 2008 and is headquartered in Menlo Park, California.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive